Evidence map›Paper›PMID 32336678›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2020

Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic.

Matthew P Cheng, Todd C Lee, Darrell H S Tan, Srinivas Murthy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Prediction and follow-up of risk factors for severe SARS-CoV-2 pneumonia and application of CT visual scoring.Technology and health care : official journal of the European Society for Engineering and Medicine · 2021
    Article
  13. Article
  14. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Article
  15. Mavrilimumab for severe COVID-19.The Lancet. Rheumatology · 2020
    Article
  16. Review
  17. Article
  18. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Article
  19. Review
  20. Excluding pregnancy from COVID-19 trials: Protection from harm or the harm of protection?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Matthew P ChengDivision of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC.
Todd C LeeDivision of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC.
Darrell H S TanDivision of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC.
Srinivas MurthyDivision of Infectious Diseases (Cheng, Lee), Department of Medicine, and Division of Medical Microbiology (Cheng), Department of Laboratory Medicine, McGill University Health Centre; Clinical Trials Platform (Cheng, Lee), McGill Interdisciplinary Initiative in Infection and Immunity, Montréal, Que.; Division of Infectious Diseases (Tan) and MAP Centre for Urban Health Solutions (Tan), St. Michael's Hospital; Department of Medicine (Tan), University of Toronto, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC srinivas.murthy@cw.bc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsPandemicsPneumonia, ViralRandomized Controlled Trials as TopicBetacoronavirusCanadaCOVID-19COVID-19 Drug TreatmentDrug ApprovalGovernment RegulationHumansResearch DesignSARS-CoV-2

Identifiers

PMID32336678
PMCPMC7162442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.